From Lab Bench to Market: Inside the ScienceWerx Commercialization Pipeline
Most scientific breakthroughs never reach the people who need them. ScienceWerx is redesigning that pipeline — from IP protection to pre-seed funding to market entry — to make commercialization the rule, not the exception.
The gap between a peer-reviewed discovery and a functioning product is not a gap of ideas — it is a gap of infrastructure. Across every scientific domain, from biotech to clean energy to agricultural technology, transformative research sits dormant in university repositories and government lab archives, underfunded and under-routed. ScienceWerx was built to close this gap, not by inventing new science, but by building the systems that turn existing science into durable economic and social value.
Our commercialization pipeline is structured around five stages: discovery, IP protection, market validation, pre-seed financing, and scale-up support. Each stage is designed with the scientist in mind — researchers are often deep experts in their domains but have limited exposure to patent strategy, investor relations, or market sizing. Our embedded commercialization advisors work directly with research teams from the earliest stages, ensuring that IP is structured correctly before any licensing conversation begins.
Market validation is where many commercialization efforts fail. A technology may be elegant and novel, yet solve a problem that the intended market does not prioritize or cannot afford. ScienceWerx deploys structured Voice of Market research at Stage 3, partnering with industry consortia and end-user communities to test assumptions before capital is committed. This approach has reduced our post-investment pivot rate by 62% over the past three funding cycles.
Pre-seed financing through the EverGreen Fund bridges the notorious "valley of death" — the period between academic funding and commercial investment where most breakthroughs disappear. The fund operates on a milestone-based disbursement model, meaning capital is deployed in tranches tied to measurable technical and commercial targets rather than calendar-based schedules. This discipline protects both the researcher and the fund while maintaining accountability across the pipeline.
Scale-up is the final and often most underestimated stage. Getting a product to market is a different discipline from getting it to scale — regulatory clearance, manufacturing partnerships, distribution networks, and international market access all require expertise that most early-stage teams lack. ScienceWerx maintains a global network of industry partners, government trade offices, and diaspora chambers of commerce to provide this infrastructure. The result is a pipeline that does not just produce products, but produces lasting commercial enterprises rooted in science.